低剂量阿比拉酸用于治疗前列腺癌:一项观察性队列研究
Luis Angel Di-Giuseppe1, Rodney Alexander Ramirez-Murillo2, Mariano Daniel Aymar2
1Department of Pharmacology-Toxicology, University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; Pharmacy and Supplies Area, Health Insurance Provider of the Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
概括
在转移性前列腺癌患者中,低剂量阿比拉乙酸的无进展生存期与标准剂量相比相当. 这一发现表明,有潜力改善治疗的可访问性,并具有类似的疗效.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 转移性前列腺癌的治疗往往涉及到阿比拉酸盐.
- 优化阿比拉酸剂量对于平衡疗效和患者获取至关重要.
研究的目的:
- 为了在转移性前列腺癌中比较低剂量和标准剂量的阿比拉乙酸之间的无进展生存率 (rPFS).
- 评估前列腺特异性抗原无进展生存期 (PSA-PFS) 与阿比拉酸盐剂量相关.
主要方法:
- 追溯队列研究包括144名转移性前列腺癌患者.
- 使用Cox比例危险回归的RPFS和PSA-PFS的分析.
- 对临床变量进行调整,包括并发症指数,割耐药性和疾病体积.
主要成果:
- 低剂量的阿比拉酸 (n=41) 显示,对于rPFS (95% CI:0.29-1.45),调整后的危险比为0.65,不显著.
- 对于PSA-PFS的原始和调整后的危险比率偏好了低剂量的阿比拉酸 (原始:0.48;调整后:0.58).
- 与标准剂量组 (75岁) 相比,低剂量组 (79岁) 的中位年龄更高.
结论:
- 低剂量阿比拉酸在转移性前列腺癌中显示出与标准剂量相比的进展结果.
- 这种较低的剂量可能会提高治疗的可用性.
- 建议对更大的队列进行进一步研究,以证实这些发现.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
826
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
826
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


